Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT00660621
Title A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kentuckiana Cancer Institute, Eisai Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.